Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: An immune-related lncRNA signature predicts prognosis and adjuvant chemotherapeutic response in patients with small-cell lung cancer

Fig. 4

Validating the irlncRNA signature in the validation cohort with qPCR data. a Kaplan–Meier curves of OS for 148 patients of the validation cohort based on risk score. b ROC analysis of risk score for prediction of survival at 1, 3, and 5 years for the validation cohort. c ROC analysis of risk score and different clinical parameters for OS for the validation cohort. d Kaplan–Meier curves of RFS for 148 patients of the validation cohort based on risk score. e ROC analysis of risk score for prediction of RFS at 1, 3, and 5 years for the independent cohort. f ROC analysis of risk score and different clinical parameters for RFS for the independent cohort. g Kaplan–Meier curves of OS for the ACT subgroup of the validation cohort based on risk score. h ROC analysis of risk score for prediction of OS at 1, 3, and 5 years for the ACT subgroup of the validation cohort. i ROC analysis of risk score and different clinical parameters for RFS for the ACT subgroup of the validation cohort

Back to article page